Rhumbline Advisers Has $59.98 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Rhumbline Advisers decreased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 448,852 shares of the life sciences company's stock after selling 7,737 shares during the quarter. Rhumbline Advisers owned 0.28% of Illumina worth $59,980,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Creative Planning boosted its holdings in Illumina by 3.3% in the third quarter. Creative Planning now owns 16,679 shares of the life sciences company's stock worth $2,175,000 after purchasing an additional 535 shares during the period. nVerses Capital LLC bought a new position in shares of Illumina in the 3rd quarter worth about $65,000. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Illumina by 28.3% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 15,370 shares of the life sciences company's stock valued at $2,004,000 after buying an additional 3,393 shares during the period. Raymond James & Associates grew its position in shares of Illumina by 39.6% during the 3rd quarter. Raymond James & Associates now owns 441,182 shares of the life sciences company's stock valued at $57,535,000 after buying an additional 125,073 shares during the last quarter. Finally, Northwest Investment Counselors LLC raised its stake in Illumina by 2.3% during the third quarter. Northwest Investment Counselors LLC now owns 13,253 shares of the life sciences company's stock worth $1,728,000 after acquiring an additional 302 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ILMN. Stephens lifted their target price on Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a research note on Tuesday, November 12th. TD Cowen downgraded Illumina from a "buy" rating to a "hold" rating and cut their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Morgan Stanley lowered their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. UBS Group increased their target price on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Finally, Guggenheim reduced their price target on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $159.45.

Illumina Price Performance

ILMN traded down $5.80 during trading on Thursday, reaching $97.20. The stock had a trading volume of 5,942,184 shares, compared to its average volume of 2,542,647. The stock has a 50 day moving average of $129.96 and a two-hundred day moving average of $134.41. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $15.40 billion, a price-to-earnings ratio of -12.66, a price-to-earnings-growth ratio of 1.67 and a beta of 1.10. Illumina, Inc. has a 1-year low of $95.23 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.